Outlook Therapeutics Announces LYTENAVA™ FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMD

Outlook Therapeutics announced FDA approval of LYTENAVA™ (bevacizumab-vikg), the first FDA-approved ophthalmic formulation of bevacizumab specifically designed for treating wet AMD. The approval provides 12 years of market exclusivity under BPCIA and positions the company to capture market share in the approximately $8.5 billion U.S. retina market. The company is launching commercial operations and expects to make LYTENAVA™ available to patients before year-end.